https://www.selleckchem.com/pr....oducts/anlotinib-al3
1% (31/308) and 6.2% (19/308) of patients, respectively. Excluding patients with solitary kidney and/or VHL, local recurrence and new lymphadenopathy/metastasis occurred in 8.6% (23/268) and 1.9% (5/268) of cases, respectively. Kaplan-Meier estimated disease-free survival was 92.5% at 1 year, 89.3% at 2 years, and 86.7% at 3 years post-PCA. Increasing tumor size was a significant predictor of disease progression (HR 1.32 per 1 cm increase in size, P = 0.001). CONCLUSIONS PCA is a viable treatment option for patients with SRMs.
Like
Comment
Share
